Quick Answer
Annovis Bio, Inc. reported Stockholders Equity of $16.85 million for the year ending 2025.
- Annovis Bio, Inc. showed an increase of +81.0% in Stockholders Equity from 2024 to 2025.
- This data is from Annovis Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2018 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$7.78 million | Q2 2019: -$8.12 million | Q3 2019: -$8.37 million | Q1 2020: $10.69 million | Q2 2020: $9.50 million | Q3 2020: $9.12 million | Q1 2021: $4.37 million | Q2 2021: $48.61 million | Q3 2021: $46.53 million | Q1 2022: $42.70 million | Q2 2022: $38.67 million | Q3 2022: $34.59 million | Q1 2023: $20.14 million | Q2 2023: $20.74 million | Q3 2023: $6.66 million | Q1 2024: -$3.35 million | Q2 2024: -$1.75 million | Q3 2024: $7.06 million | Q1 2025: $24.05 million | Q2 2025: $18.33 million | Q3 2025: $13.16 million.
- Over the full 11 years of available data (2018 to 2025), Annovis Bio, Inc.'s Stockholders Equity has grown by 321.9%.
- Historical annual values: Fiscal year 2025: $16.85 million | Fiscal year 2024: $9.31 million | Fiscal year 2023: -$7.75 million | Fiscal year 2022: $28.32 million | Fiscal year 2022: $34.59 million | Fiscal year 2022: $38.67 million | Fiscal year 2022: $42.70 million | Fiscal year 2021: $44.49 million | Fiscal year 2020: $7.54 million | Fiscal year 2019: -$8.58 million | Fiscal year 2018: -$7.59 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: